{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.83","upperLimit":"-0.09","value":"-0.46"},{"groupId":"OG001","lowerLimit":"-0.49","upperLimit":"-0.03","value":"-0.26"},{"groupId":"OG002","lowerLimit":"-1.02","upperLimit":"-0.38","value":"-0.70"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"47"},{"groupId":"OG002","value":"58"}],"units":"Participants"}],"description":"The PII assesses relevant aspects of one's life, including pain interference with activities, spending time with family/friends, mood, sleep and attention. Participants ≥ 6 years of age complete a self-report, and parents/guardians of children aged 6-17 complete a parent proxy report. The recall period is 24 hours. The PII consists of 6 questions, each asking the responder to select one number from 0 to 6 that best describes how their/their proxy's pain has impacted various items over the past 24 hours with 0 representing \"Not at all\" and 6 representing \"Completely\". The mean of the completed items is taken as the PII score for a single assessment. The PII score presented each visit will be taken as the average of the PII scores over the 7 consecutive days up to and including visit day, with no transformation applied. The change from baseline is modelled using a mixed-model for repeated measures.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients self-reported results aged 6 to 17 years old at the time of informed consent. Mirdametinib (PD-0325901) capsule or dispersible tablet 2 mg/m\\^2 (maximum dose of 4 mg) by mouth twice daily","id":"OG000","title":"Treatment Phase - Pediatric Cohort Mirdametinib (PD-0325901) - Self-Report"},{"description":"Patients parent proxy results aged 6 to 17 years old at the time of informed consent. Mirdametinib (PD-0325901) capsule or dispersible tablet 2 mg/m\\^2 (maximum dose of 4 mg) by mouth twice daily","id":"OG001","title":"Treatment Phase - Pediatric Cohort Mirdametinib (PD-0325901) - Parent Proxy"},{"description":"Patients self-reported results aged 18 years and above at the time of informed consent. Mirdametinib (PD-0325901) capsule or dispersible tablet 2 mg/m\\^2 (maximum dose of 4 mg) by mouth twice daily","id":"OG002","title":"Treatment Phase - Adult Cohort Mirdametinib (PD-0325901) - Self-Report"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The Full Analysis Set patients eligible for the instrument at baseline.","reportingStatus":"POSTED","timeFrame":"Baseline and Cycle 13 (1 cycle = 28 days), up to 12 months","title":"Change From Baseline in Pain as Measured by the Pain Interference Index (PII) at Cycle 13.","type":"SECONDARY","unitOfMeasure":"units on a scale"}